Oxybutynin gel for the treatment of overactive bladder

Bibliography

• Haylen BT, de Ridder D, Freeman RM, An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin 2007;23:65-76
   PubMed Web of Science ®Google Scholar
• Koyne KS, Sexton CC, Irwin DE, The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101:1388-95
   PubMed Web of Science ®Google Scholar
• Sexton CC, Coyne KS, Vats V, Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care 2009;15:S98-107
   PubMedGoogle Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000;6:S574-9
   PubMed Web of Science ®Google Scholar
• Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 2005;25:511-19
   PubMed Web of Science ®Google Scholar
• Hu TW, Wagner TH, Bentkover JD, Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 2004;63:461-5
   PubMed Web of Science ®Google Scholar
• Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor – which is the main mechanism of action? Eur Urol 2003;43:1-5
   PubMed Web of Science ®Google Scholar
• Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 2006;147:S80-7
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006
   PubMed Web of Science ®Google Scholar
• de Groat WC, Theobald RJ. Reflex activation of sympathetic pathways to vesical smooth muscle and parasympathetic ganglia by electrical stimulation of vesical afferents. J Physiol 1976;259:223-37
   PubMed Web of Science ®Google Scholar
• de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006;147:S25-40
   PubMed Web of Science ®Google Scholar
• Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53
   PubMed Web of Science ®Google Scholar
• Mansfield KJ, Liu L, Mitchelson FJ, Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes with ageing. Br J Pharmacol 2005;144:1089-99
   PubMed Web of Science ®Google Scholar
• Bschleipfer T, Schukowski K, Weidner W, Expression and distribution of cholinergic receptors in the human urothelium. Life Sci 2007;80:2303-7
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-90
   PubMed Web of Science ®Google Scholar
• Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial, and prejunctional. Auton Autacoid Pharmacol 2002;22:133-45
   PubMedGoogle Scholar
• Finney SM, Andersson KE, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 2006;98:503-7
   PubMed Web of Science ®Google Scholar
• Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000;129:416-19
   PubMed Web of Science ®Google Scholar
• Nitti VW, Sanders S, Staskin DR, Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 2006;67:657-64
   PubMed Web of Science ®Google Scholar
• Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-62
   PubMed Web of Science ®Google Scholar
• Noronha-Blob L, Kachur JF. Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther 1991;256:562-7
   PubMed Web of Science ®Google Scholar
• Gelnique™ (oxybutynin chloride) Gel 10% [prescribing information]. Watson Pharmaceuticals, Inc.; Corona, CA: 2011
   Google Scholar
• Staskin DR, Robinson D. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 2009;10:3103-11
   PubMed Web of Science ®Google Scholar
• Ditropan package insert (Marion Merrell Dow - U.S.), 1992. PDR
   Google Scholar
• Zobrist RH, Schmid B, Feick A, Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001;18:1029-34
   PubMed Web of Science ®Google Scholar
• Mukhtar H, Khan WA. Cutaneous cytochrome P-450. Drug Metab Rev 1989;20:657-73
   PubMed Web of Science ®Google Scholar
• Douchamps J, Derenne F, Stockis A, The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1998;35:515-20
   Google Scholar
• Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997;157:1093-7
   PubMed Web of Science ®Google Scholar
• Rovner ES, Wein AJ. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002;41:6-14
   PubMed Web of Science ®Google Scholar
• Alberti I, Grenier A, Kraus H, Carrara DN. Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opin Drug Deliv 2005;2:935-50
   PubMed Web of Science ®Google Scholar
• Kennelly MJ. Oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol 2010;12:12-19
   PubMedGoogle Scholar
• Yong C, Yu D, Eden L, Effect of food on the pharmacokinetics of oxybutynin in normal subjects. Pharm Res 1991;8:S-320
   Google Scholar
• Dmochowski RR, Newman DK, Sand PK, Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference. Clin Drug Investig 2011;31:559-71
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;4:CD003781
   PubMed Web of Science ®Google Scholar
• Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006;4:CD003193
   PubMedGoogle Scholar
• Chapple CR, Khullar V, Gabriel Z, The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Serels SR, Toglia MR, Forero-Schwanhaeuser S, Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Curr Med Res Opin 2010;26:2277-85
   PubMed Web of Science ®Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol 2009;181:1764-72
   PubMed Web of Science ®Google Scholar
• Sand PK, Davila GW, Lucente VR, Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol 2012;206:168.e1-6
   PubMed Web of Science ®Google Scholar
• Caramelli KE, Staskin DR, Volinn W. Steady-state pharmacokinetics of an investigational oxybutynin topical gel in comparison with oxybutynin transdermal system [abstract 1508]. Poster presented at AUA Annual Meeting; 2008
   Google Scholar
• Abrams P, Andersson KE, Buccafusco JJ, Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565-78
   PubMed Web of Science ®Google Scholar
• Scarpero HM, Dmochowski RR. Muscarinic receptors: what we know. Curr Urol Rep 2003;4:421-8
   PubMedGoogle Scholar
• Meek PD, Evang SD, Tadrous M, Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011;56:7-18
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42
   PubMed Web of Science ®Google Scholar
• Kay G, Staskin D, MacDiarmid S, Are the effects of oxybutynin on cognition dependent upon the route of administration - topical or oral? A double-blind placebo controlled study employing sensitive cognitive and psychomotor testing [abstract 111]. Poster presented at 39th Annual Meeting of the ICS; 2009
   Google Scholar
• Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care 2005;11:S140-9
   Web of Science ®Google Scholar
• Yu YF, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005;8:495-505
   PubMed Web of Science ®Google Scholar
• Shaya FT, Blume S, Gu A, Persistence with overactive bladder pharmacotherapy in a Medicaid population. Am J Manag Care 2005;11:S121-9
   PubMed Web of Science ®Google Scholar
• Sears CL, Lewis C, Noel K, Overactive bladder medication adherence when medication is free to patients. J Urol 2010;183:1077-81
   PubMed Web of Science ®Google Scholar
• Available from: http://www.antarespharma.com/files/4213/1039/3845/Antares_oxybutynin_gel_License.pdf
   Google Scholar
• Staskin D, Dave K. Dose formulation, dose selection, and phase III results for a flexible dose gel for transdermal oxybutynin delivery [abstract 161]. Poster presented at the 41st Annual Meeting of the ICS; 2011
   Google Scholar